Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VALOR pediatric vericiguat trial in heart failure due to systemic left ventricular systolic dysfunction
2022-501238-52-00Phase 3Authorised
- Sponsor
- Merck & Co.
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 31
01
Overview
Phase 3, randomised, double-blind trial in heart failure with reduced ejection fraction (HFrEF) comparing Vericiguat with Placebo (2 arms). Primary endpoints: Change from baseline to Week 16 in log-transformed NT-proBNP, Percentage of participants with one or more adverse events and 1 more. Planned start Mar 2023; status: authorised.
02
Drugs
vericiguat
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on 2022-501238-52-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501238-52-00.